评估单组分口服霍乱疫苗BBV131(Hillchol®)与Shanchol™相比的安全性、免疫原性、非劣效性和批间一致性的双盲随机III期临床试验
在印度10个临床试验点招募1800名健康成人和儿童,按3:1随机分配接受BBV131或Shanchol™,第0天和第14天口服两剂。BBV131组抗Ogawa和Inaba杀弧菌抗体滴度>4倍增长的比例分别为68.25%和69.52%,非劣效于Shanchol™,安全性相似。
要点
- BBV131组第2剂后14天抗Ogawa和Inaba抗体滴度>4倍增长比例分别为68.25%和69.52%,非劣效于Shanchol™。
- 236名参与者(13.1%)报告257例不良事件,各年龄组和疫苗间发生率相似,常见不良事件为口干和头痛。
- 1800名参与者中1794名完成研究,BBV131在健康印度成人和儿童中显示非劣效免疫原性和可比安全性。
核心结论
- BBV131在健康印度成人和儿童中显示与Shanchol™非劣效的免疫原性和可比的安全性,支持其作为有效口服霍乱疫苗的潜力。
研究设计与样本
- 随机、改良双盲、多中心III期临床试验,在印度10个临床试验点招募1800名参与者,分层为三个年龄组(成人>18岁、儿童≥5至<18岁、婴幼儿≥1至<5岁),按3:1随机分配接受BBV131或Shanchol™。
- 所有参与者第0天和第14天口服两剂疫苗,免疫原性通过基线、每剂后两周及第28、56、90和180天随访的血样评估,主要终点为两剂后14天抗Ogawa和Inaba血清型杀弧菌抗体滴度>4倍增长的比例。
- 另添加1800名参与者队列以扩大安全性数据库。
主要发现
- 1800名入组参与者中1794名完成研究。
- BBV131组抗Ogawa和Inaba抗体滴度>4倍增长的比例分别为68.25%和69.52%,非劣效于Shanchol™,95%CI下限高于非劣效界值。
- 236名参与者(13.1%)报告257例不良事件,各年龄组和疫苗间发生率相似,常见不良事件包括口干和头痛。
关键数值与推荐
- 主要终点:两剂后14天抗Ogawa和Inaba杀弧菌抗体滴度>4倍增长的比例,BBV131组分别为68.25%和69.52%,非劣效于Shanchol™(95%CI下限高于非劣效界值)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cholera is a vaccine-preventable disease that has faced a surge in outbreaks and a shortage of vaccines. The new generation oral cholera vaccine (OCV) BBV131, featuring a simplified single stable O1 Hikojima strain, aims to enhance production efficiency and affordability. This study evaluates BBV131's immune profile, safety, and non-inferiority compared to Shanchol™ in healthy adults and children. Adding BBV131 to the vaccine stockpile could improve supply, simplify logistics, and ease administration efforts. METHODS: In this randomised, modified, double-blind, multi-centre, phase III trial, 1800 participants were recruited across 10 clinical trial sites across India. Participants were stratified into three age groups (adults >18 years, children ≥5 to <18 years, and infants ≥1 to <5 years) and were randomised in a 3:1 ratio to receive either BBV131 or Shanchol™. All participants received two doses of the vaccine orally on days 0 and 14. Immunogenicity was assessed through blood samples collected at baseline, two weeks after each dose, and follow-ups at days 28, 56, 90, and 180. The primary endpoint focused on the proportion of participants achieving >4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14 days post two doses. While secondary endpoints included Geometric Mean Titre (GMT) measurements and safety. Safety was evaluated throughout the study, reporting solicited and unsolicited adverse events (AEs). Another cohort of 1800 was added to the above study as an addendum to expand the safety database. FINDINGS: Of the 1800 enrolled participants, 1794 completed the study. Post-vaccination, the percentage of participants in the BBV131 group who exhibited a > 4-fold increase in anti-V. cholerae antibody titres were 68.25 % for Ogawa and 69.52 % for Inaba-demonstrating non-inferiority to Shanchol™, with a lower limit of 95 % CI above the non-inferiority margin. The safety profile revealed 257 AEs among 236 participants (13.1 %), with similar incidence across age groups and between vaccines; common AEs included dry mouth and headache. INTERPRETATION: The findings indicate that BBV131 demonstrates non-inferior immunogenicity and comparable safety to Shanchol™ in healthy Indian adults and children, supporting its potential as an effective OCV. CLINICAL TRIAL REGISTRATION: CTRI/2022/01/039734.
引用
- Vadrevu KM, Chavan A, Chawla A, et al. A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™. Vaccine. 2025. PMID: 40174256. doi:10.1016/j.vaccine.2025.126998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。